These results are consistent with other studies’ findings that the prevalence of MYD88 L265P mutations in DLBCL patients ranged from 6.5% to 19%.[5,9,36,37] In our study, the mutation frequency was similar between GCB and non-GCB DLBCL groups. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.